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Activation of a protein kinase G signalling pathway has
been demonstrated to ameliorate a broad range of car-
diac disease conditions, including ischemia and infarc-
tion, doxorubicin toxicity, protein misfolding disorders,
pressure-overload, dilated heart failure, and dystrophin
deficiency. The pathway's activation depends upon
cGMP generated by either NO-sGC or NP-rGC signal-
ling. Growing evidence shows that the former is a target
of oxidative stress, depressing the functionality of NO-
synthase, NO (by interaction with oxidant species), and
sGC. We recently examined the impact of PKG1 oxida-
tion, a disulphide modification at C42 residues in the
homodimer subunits, on cardiac stress response. While
this oxidation has been previously shown to provide a
gain of function in resistance arterioles, in the myocar-
dium, prevention of this oxidation in mice or myocytes
expressing a C42S mutant knock-in was protective
against pressure overload. The mechanism was not
explained on the basis of a change in kinase activity, but
rather by differential intracellular targeting likely related
to protein interactions. A key target, transient receptor
potential canonical-6 ion channel, which transduces
hypertrophic and fibrotic signalling via the calcineurin/
NFAT pathway, was more suppressed when PKG1 was
not oxidized. PKG1 oxidation also appears to alter the
capacity of various ways of stimulating the kinase, includ-
ing PDE inhibition, and sGC or NP stimulation. This
introduces PKG1 redox as a major regulator of its signal-
ling effects, that also pathway and ways to activate it.
In a second set of studies, we have recently revealed
that the highly cGMP selective - PDE9A – is expressed
in human and mouse hearts, upregulated in diseased
hearts, and plays a role in maladaptive hypertrophy,
fibrosis, and dysfunction in hearts exposed to sustained
pressure stress. Furthermore, its genetic or selective phar-
macological suppression ameliorates this cardiac patho-
physiology. Unlike PDE5A, PDE9A targets the NP
signalling pathway, effectively bypassing suppression of the
NO-sGC cascades as often occurs in diseased hearts due
to oxidative stress. PDE9A inhibition remains effective in
vivo and in vitro even if NOS is blocked. These studies
reveal two novel approaches to better leverage PKG1 acti-
vation in the diseased heart, suppression of oxidative
modifications of the kinase at C42, and blocking PDE9A
to circumvent declines in NO-sGC signalling.
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